Protai, a Tel Aviv, Israel-based AI-powered drug discovery startup, raised $8M in Seed funding.
The round was led by Grove Ventures and Pitango HealthTech.
The company intends to use the funds to further develop its platform, accelerate its discovery programs and enhance its partnerships with pharmaceutical companies.
Led by Eran Seger, CEO, Protai provides a Proteomics-based platform for faster and more accurate drug discovery to unlock new layers of biological insights and to combat complex diseases. The company has built an end-to-end AI-based platform that comprehensively maps the course of a disease on the protein level, enhancing the ability to observe cellular function and thereby improving the way new drugs are discovered.
Protai has created a large and diverse proteomic database with over 50,000 clinical samples by harmonizing large clinical datasets, as well as healthy samples from various organs and indications. This enables the company to establish a baseline to then accurately simulate biological functional processes for a variety of diseases and accelerate drug R&D through clinical and preclinical stages.
Protai’s Advisory Board includes:
- Prof. Tami Geiger, an expert in cancer proteomics research at the Weizmann Institute of Science,
- Professor Alexey Nesvizhskii, a global leader in computational proteomics from the University of Michigan, and
- Prof. Avi Ma’ayan, the Director of the Mount Sinai Center for Bioinformatics at the Icahn School of Medicine at Mount Sinai, and an expert in the application of machine learning for drug discovery.